Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients

Abstract

Discussion, the sentence ,<vascular endothelial growth factor receptor monoclonal antibody bevacizumab~ must be replaced by ~vascular endothelial growth factor monoclonal antibody bevacizumab~ since bevacizumab is directed towards the ligand, not the receptor.

Biweekly Administration of Irinotecan (Cpt-11) Plus Cisplatin With an Antidiarrheal Program of Intestinal Alkalization to Reduce Diarrhea in Cancer Patients

“…Magnesium oxide demonstrates a laxative action, which should shorten the dwelling time of CPT-11 and SN-38 within the intestine. The intestinal alkalization has succeeded in reducing late diarrhea by CPT-11 in pleural studies 14,[21][22][23][24] . We previously conducted a phase I/II study of biweekly CPT-11 with CDDP without the intestinal alkalization 9) .…”